ABT-229 FOR POSTPRANDIAL DIGESTIVE SYMPTOMS ASSOCIATED WITH FUNCTIONAL DYSPEPSIA

功能性消化不良或非溃疡性消化不良是一种上消化道疾病 以持续的或反复出现的症状为特征的疾病 上腹部不适不能归因于结构性或 生化异常。目前没有明确的基础 解释这一现象的病理生理机制已被阐明。 并且没有确凿的证据可以证明 确切有效的治疗方案。ABT-229是一种新型的大环内酯类抗生素 有胃动素激动剂活性，没有任何重要的抗生素 活动。本研究的目的是评估安慰剂的疗效。 ABT-229与安慰剂治疗餐后消化不良的比较 功能性消化不良相关症状和安全性评估 ABT-229在这些患者中的表达。

Functional dyspepsia or nonulcer dyspepsia is an upper gastrointestinal disorder that is characterized by persistent or recurrent symptoms of upper abdominal discomfort which cannot be attributed to structural or biochemical abnormalities. Currently no definitive underlying pathophysiological mechanisms have been elucidated to explain this disorder and there is no conclusive evidence available identifying a definitive efficacious treatment regimen. ABT-229 is a novel macrolide with motilin agonist activity and devoid of any significant antibiotic activity. The objectives of this study are to assess the efficacy of ABT-229 compared to placebo for the treatment of postprandial digestive symptoms associated with functional dyspepsia and to assess the safety of ABT-229 in these patients.